NanoString Technologies, Inc. (NASDAQ:NSTG) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
in the J.P. Morgan Healthcare Conference, the Company announced
on January 10, 2017>certain preliminary results at and for the
year ended December 31, 2016. A copy of the press release is
furnished herewith as Exhibit 99.1 and is incorporated herein by
reference. The information in Items 2.02 and 7.01 of this Form
8-K and the attached exhibit are furnished to, but not filed
with, the Securities and Exchange Commission.
Commission, the attached exhibit is deemed to have been furnished
to, but not filed with, the Securities and Exchange Commission:
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press release dated January 10, 2017.
|
About NanoString Technologies, Inc. (NASDAQ:NSTG)
NanoString Technologies, Inc. develops and manufactures intuitive products that unlock scientifically valuable and clinically actionable biologic information from minute amounts of tissue. The Company operates in the segment of development, manufacture and commercialization of instruments, consumables and services for profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample. Its nCounter Analysis System is an automated, multi-application, digital detection and counting system, which directly profiles hundreds of molecules simultaneously using a barcoding technology. It markets systems and related consumables to researchers in academic, government and biopharmaceutical laboratories for use in understanding fundamental biology, and to clinical laboratories and medical centers for diagnostic use. Its molecular diagnostic product Prosigna Breast Cancer Assay provides an assessment of a patient’s risk of recurrence for breast cancer. NanoString Technologies, Inc. (NASDAQ:NSTG) Recent Trading Information
NanoString Technologies, Inc. (NASDAQ:NSTG) closed its last trading session up +0.24 at 22.99 with 130,750 shares trading hands.
